D-0094-2023 Class III Terminated

Recalled by Camber Pharmaceuticals, Inc — Piscataway, NJ

FDA drug recall D-0094-2023 was initiated by Camber Pharmaceuticals, Inc on Dec 6, 2022 and is designated Class III. Reason for recall: Failed Excipient Specifications: out of specification result observed for p-Hydroxybenzoic Acid content The recall status is terminated (terminated Mar 15, 2024).

Recall details

Product Type
Drugs
Report Date
Dec 21, 2022
Initiation Date
Dec 6, 2022
Termination Date
Mar 15, 2024
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Lacosamide Oral Solution, USP, CV, 10mg/mL, packaged in 200 mL bottle, Rx Only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854, Manufactured By: HETERO LABS LIMITED, Jeedimetla, Hyderabad - 500 055, India, NDC 31722-627-26

Reason for recall

Failed Excipient Specifications: out of specification result observed for p-Hydroxybenzoic Acid content

Distribution pattern

USA Nationwide

Code information

Lot#: E222200, E222199, Exp 05/2024; E222228, Exp 06/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0094-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0094-2023. Report a data issue: hello@regdatalab.com.